Neurology News Network for the week ending June 6th, 2026. [WATCH TIME: 5 minutes]
NeurologyLive® Staff
Advertisement
Articles by NeurologyLive® Staff
GLP-1s Improve MS Physical Activity, BLA Submitted for Z-Rostudirsen, Ofatumumab Outperforms Rituximab in NMOSD Study
Published: | Updated:
Neurology News Network for the week ending May 30, 2026. [WATCH TIME: 4 minutes]
Neurology News Network for the week ending May 16th, 2026. [WATCH TIME: 4 minutes]
Experts debate how to sequence new gMG therapies, manage seronegative and special populations, and close biomarker and access gaps.
Neurology News Network for the week ending May 16th, 2026. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending May 9th, 2026. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending May 2nd, 2026. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending April 25th, 2026. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending April 18, 2026. [WATCH TIME: 5 minutes]
Modafinil Effective for Treating EDS, Ravulizumab Controls NMOSD, Regardless of Rituximab Use, Reviewing 2026 Q1 FDA Approvals
Published: | Updated:
Neurology News Network for the week ending April 11, 2026. [WATCH TIME: 4 minutes]
FDA Approves Higher Dose Nusinersen, Fatigue, EDS Uncorrelated with OSA, Shifting Neurologic Research in Down Syndrome
Published: | Updated:
Neurology News Network for the week ending April 4, 2026. [WATCH TIME: 5 minutes]
FDA Approvals Highlight Rare Neurologic Therapies as Purple Day Raises Awareness for Epilepsy
Published: | Updated:
Neurology News Network for the week ending March 28, 2026. [WATCH TIME: 4 minutes]
Solriamfetol Reduces EDS, Xanomeline Trospium evaluated for Agitation in AD, Otaneda Explains radiologic markers in MS trials
Published: | Updated:
Neurology News Network for the week ending March 21, 2026. [WATCH TIME: 4 minutes]
FDA Expands Leucovorin Indication, Key Phase 3 Studies Revealed at MDA 2026, Crowley on the Future of Neuromuscular Medicine
Published: | Updated:
Neurology News Network for the week ending March 14, 2026. [WATCH TIME: 4 minutes]
Fenebrutinib Achieves Primary End Point in Head-to-Head Trial, GB221 Begins First-in-Person Trial for SMA1, Air Pollution Linked to Increased AD Risk
Published: | Updated:
Neurology News Network for the week ending March 7, 2026. [WATCH TIME: 5 minutes]
Efgartigimod Meets Primary Endpoint, Neurologic Outcomes not Improved with EryDex, Elevidys Associated with Stabilization in DMD
Published: | Updated:
Neurology News Network for the week ending February 28, 2026. [WATCH TIME: 5 minutes]
Balt's Squid Receives Premarket Approval, Pitolisant Tablets Granted Extended Approval Indication, I-ACQUIRE Displays Promising Short-Term Outcomes
Published: | Updated:
Neurology News Network for the week ending February 21, 2026. [WATCH TIME: 5 minutes]
Regenxbio Receives CRL from FDA, NDA for Takeda’s Oveporextin Accepted, ACP Abandons use of “Provider”
Published: | Updated:
Neurology News Network for the week ending February 14, 2026. [WATCH TIME: 4 minutes]
Phase 3 EMBARK Data Released, CTE Associated with Dementia Risk, Pilavapadin Heads to Phase 3 Pain Studies
Published: | Updated:
Neurology News Network for the week ending January 31, 2025. [WATCH TIME: 4 minutes]
Phase 3 Data Levacetylleucine Data in Niemann-Pick, FDA Requests Data for Deramiocel to Fulfill Submission, COYA 302 and Frontotemporal Dementia
Published: | Updated:
Neurology News Network for the week ending January 24, 2025. [WATCH TIME: 4 minutes]
Efgartigimod Application Submitted for Seronegative gMG, EC Approves High-Dose Nusinersen, Copper Histidinate Gains First Approval for Menkes Disease
Published: | Updated:
Neurology News Network for the week ending January 17, 2025. [WATCH TIME: 4 minutes]
Phase 2 BREAKTHROUGH Data Released, Liriglutide Effective in Obesity-Related Migraine, FDA Approves Generic Glatiramer Acetate Injection
Published: | Updated:
Neurology News Network for the week ending January 10, 2025. [WATCH TIME: 4 minutes]
REVITALYZ Trial Enrollment Complete, PIPE-307 Fails Phase 2 Trial, AMX0114 Safe in Phase 1 LUMINA Study
Published: | Updated:
Neurology News Network for the week ending January 3, 2025. [WATCH TIME: 4 minutes]
NeurologyLive® Year in Review 2025: Top trending Migraine Trials
Published: | Updated:
As part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.
NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.
NeurologyLive® Year in Review 2025: Roundtable Roundup – Reviewing this Year’s Launched Programming
Published: | Updated:
Discover key conversations from leaders in neurology covering a range of different clinically relevant topics.
Neurology News Network for the week ending December 27, 2025. [WATCH TIME: 4 minutes]
A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews regarding multiple sclerosis in 2025.
As part of NeurologyLive®'s Year in Review, we've compiled some notable trials that began in 2025.
Advertisement
Latest Updated Articles
NeurologyLive® Friday 5 — June 28, 2024Published: June 28th 2024 | Updated: July 2nd 2024
ND0612 Receives Complete Letter Response, Otsuka Terminates AVP-786, TSHA-102 Performs in Phase 1/2 REVEAL StudiesPublished: June 23rd 2024 | Updated: June 24th 2024
Abstracts for the 2024 CMSC Annual Meeting Are Now Live!Published: May 26th 2024 | Updated: May 28th 2024
The 2024 CMSC Annual Meeting Abstract GuidePublished: May 26th 2024 | Updated: May 28th 2024
Momentus Progress Within the MS Space Led by AHNNovember 1st 2021
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Differentiating Pathologic Features of Alzheimer Disease and Lewy Body Dementia: Charbel Moussa, MBBS, PhD
2
Improving Recognition and Treatment of Hyperkinetic Movement Disorders: Zoltan Mari, MD
3
Donanemab Shows Durable Amyloid Clearance and Consistent Safety in Early-Start Patients
4
Current and Emerging Strategies for Managing Huntington Disease Symptoms: Karen Anderson, MD
5